Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Mylan Specialty
- 24 May 2017 Primary endpoint (Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks) has been met, according to theresults presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Primary endpoint (Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation) has been met, according to the results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results evaluating the long-term safety of Perforomist inhalation therapy in patients with chronic obstructive pulmonary disease, presented at the 113th International Conference of the American Thoracic Society.